Specific chemotherapy of Chagas disease: a comparison between the response in patients and experimental animals inoculated with the same strains
- PMID: 1287919
- DOI: 10.1016/0035-9203(92)90156-7
Specific chemotherapy of Chagas disease: a comparison between the response in patients and experimental animals inoculated with the same strains
Abstract
Eleven strains of Trypanosoma cruzi were isolated from patients with Chagas disease in central Brazil by xenodiagnosis and inoculation into newborn mice. Biological characterization and isoenzyme analysis showed that 6 strains were type II (zymodeme 2) and 5 were type III (zymodeme 1). Patients were treated with benznidazole or benznidazole plus nifurtimox. Mice infected with each isolated strain were treated for comparison with the results obtained in the respective patient. Evaluation of cure of the patients was based on the indirect immunofluorescence test, complement fixation reaction and xenodiagnosis. For the mice, haemoculture, indirect immunofluorescence testing, xenodiagnosis and inoculation of blood into newborn mice were used. Tests were performed 3-6 months after the end of treatment. The cure rate was 66-100% in mice infected with type II strains and 0-9% in those infected with type III strains. The correlation between treatment results in patients and mice was 81.8% (9 of 11 cases). Type II strains were more susceptible to treatment, in contrast to type III strains which yielded the majority of therapeutic failures.
Similar articles
-
Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types.Bull World Health Organ. 1985;63(4):721-6. Bull World Health Organ. 1985. PMID: 3936634 Free PMC article.
-
Response to chemotherapy with benznidazole of clones isolated from the 21SF strain of Trypanosoma cruzi (biodeme Type II, Trypanosoma cruzi II).Rev Soc Bras Med Trop. 2005 Mar-Apr;38(2):142-6. doi: 10.1590/s0037-86822005000200003. Epub 2005 Mar 30. Rev Soc Bras Med Trop. 2005. PMID: 15821788
-
[Therapy of the chronic phase of the experimental infection by Trypanosoma cruzi with benzonidazole and nifurtimox].Rev Soc Bras Med Trop. 1989 Jul-Sep;22(3):113-8. doi: 10.1590/s0037-86821989000300001. Rev Soc Bras Med Trop. 1989. PMID: 2518608 Portuguese.
-
An update on benznidazole for the treatment of patients with Chagas disease.Drugs Today (Barc). 2018 Jan;54(1):15-23. doi: 10.1358/dot.2018.54.1.2753402. Drugs Today (Barc). 2018. PMID: 29569658 Review.
-
Current status of Chagas disease chemotherapy.Expert Rev Anti Infect Ther. 2011 May;9(5):609-20. doi: 10.1586/eri.11.31. Expert Rev Anti Infect Ther. 2011. PMID: 21609270 Review.
Cited by
-
Trypanosoma cruzi I and IV stocks from Brazilian Amazon are divergent in terms of biological and medical properties in mice.PLoS Negl Trop Dis. 2013;7(2):e2069. doi: 10.1371/journal.pntd.0002069. Epub 2013 Feb 21. PLoS Negl Trop Dis. 2013. PMID: 23437410 Free PMC article.
-
New insights into Trypanosoma cruzi genetic diversity, and its influence on parasite biology and clinical outcomes.Front Immunol. 2024 Apr 9;15:1342431. doi: 10.3389/fimmu.2024.1342431. eCollection 2024. Front Immunol. 2024. PMID: 38655255 Free PMC article. Review.
-
Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection.Cochrane Database Syst Rev. 2014 May 27;2014(5):CD003463. doi: 10.1002/14651858.CD003463.pub2. Cochrane Database Syst Rev. 2014. PMID: 24867876 Free PMC article.
-
Human antiprotozoal therapy: past, present, and future.Clin Microbiol Rev. 1995 Jul;8(3):427-39. doi: 10.1128/CMR.8.3.427. Clin Microbiol Rev. 1995. PMID: 7553575 Free PMC article. Review.
-
Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments.PLoS Negl Trop Dis. 2013 Aug 15;7(8):e2367. doi: 10.1371/journal.pntd.0002367. eCollection 2013. PLoS Negl Trop Dis. 2013. PMID: 23967360 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical